Library
4-Benzilpiperidin
In vitro release assays show EC50 values of approximately 41 nM for norepinephrine and 109 nM for dopamine with over 40-fold lower efficacy at SERT. Weak MAO-A inhibition appears at approximately 130 μM, relevant only at very high doses. Oral threshold of 25-50 mg produces mild wakefulness while 75-200 mg common range yields pronounced alertness, pupil dilation, and appetite suppression. Intranasal use causes sharp burning; IV administration (≤40 mg) delivers rapid onset clean stimulation lasting approximately 2 hours but risks vasospasm. Systolic blood pressure rises of 20-30 mm Hg are typical.
Also known as: 4-pmpd
Classification
- Psychoactive: Stimulant
- Tag: Benzylpiperidine
- Tag: Habit-Forming
- Tag: Piperidine
- Tag: Research-Chemical
- Tag: Tentative
Effects
- Stimulation
- Pupil Dilation
- Increased Heart Rate
- Teeth Grinding
- Muscle Tension
- Increased Energyalertness
- Wakefulness
- Focus Enhancement
- Motivation Enhancement
- Cognitive Euphoria
- Anxiety
- Cognitive Fatigue
- Appetite Suppression
- Increased Sexuality
- Visual And Auditory Hallucinations
- Light Sensitivity
- Increased Libido
- Auditory Hallucination
Routes of Administration
Oral / Sublingual
Dosage
- Threshold: 25 mg
- Light: 25-75 mg
- Common: 75-200 mg
- Strong: 200-400 mg
- Heavy: 400 mg
Duration
- Onset: 0.25-0.5 h
- Comeup: 0.5-0.75 h
- Peak: 1-2 h
- Offset: 1-3 h
- After Effects: 1-4 h
Insufflated
Dosage
- Threshold: 5 mg
- Light: 5-20 mg
- Common: 20-60 mg
- Strong: 60-120 mg
- Heavy: 120 mg
Duration
- Onset: 0.08-0.17 h
- Comeup: 0.17-0.33 h
- Peak: 1-2 h
- Offset: 1-3 h
- After Effects: 1-4 h
Intravenous
Dosage
- Threshold: 5 mg
- Light: 5-40 mg
- Common: 40-120 mg
- Strong: 120-250 mg
- Heavy: 250 mg
Duration
- Onset: 0.02 h
- Comeup: 0.02-0.08 h
- Peak: 1-2 h
- Offset: 1-3 h
- After Effects: 1-4 h
Oral
Dosage
- Common: 125-200 mg
- Heavy: 350 mg
- Light: 75-125 mg
- Strong: 200-350 mg
Duration
No data available for this section yet.
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
Links
This static page is intended as a readable non-JS and prerender-friendly library export.
